Gene test could personalize Anti-Nausea treatment for breast cancer chemo

NCT ID NCT07455955

Recruiting now Symptom relief Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a genetic test can help doctors choose the best anti-nausea drugs for Chinese women with early breast cancer undergoing chemotherapy. About 200 participants will either receive standard anti-nausea medication or a personalized regimen based on their genetic profile. The goal is to see if the personalized approach reduces vomiting and nausea and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Standard antiemetic regimen (aprepitant, ondansetron, dexamethasone) with or without olanzapine
What this could lead to: If successful, this could lead to a personalized approach to prevent chemotherapy-induced nausea and vomiting, improving comfort and quality of life for breast cancer patients.
What could go wrong: This is a small, early-phase study (Phase 2) with only 200 Chinese breast cancer patients, so results may not apply to other groups. The genetic test may not reliably predict which antiemetic works best, and olanzapine can cause side effects like drowsiness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Department of Clinical Oncology, Prince of Wales Hospital
RECRUITING

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.